Ask My Investor AI
Private companyPublished company research
PRIVATE

Verified via the issuer website (axenahealth.com) and the U.S. FDA openFDA 510(k) database. Axena Health, Inc. is privately held and venture-backed (AXA IM Alts, KOFA Healthcare, Avestria Ventures, Cross-Border Impact Ventures, Mayo Clinic); no SEC/EDGAR registration or exchange listing exists, so the seed's empty ticker is correctly not applicable and CIK is null. Caveat: the Leva 510(k) clearances remain of record under original applicant Renovia, Inc. in openFDA; Axena acquired and commercializes these assets per issuer and secondary disclosures. HQ is Newton, Massachusetts, USA; reporting currency is null because no public financial statements are filed (all disclosed capital raises are denominated in USD).

Axena Health, Inc.

Axena Health is a private, venture-backed women's-health medtech commercializing the Leva Pelvic Health System, an FDA-cleared prescription digital therapeutic (device plus app) for female stress/mixed/mild-to-moderate urinary incontinence and chronic fecal incontinence. The case rests on genuine formalization building blocks: multiple FDA 510(k) clearances (including a 2021 Breakthrough Device Designation for chronic fecal incontinence), clinical evidence published in ACOG's Obstetrics & Gynecology, expanding payer coverage, a dedicated HCPCS reimbursement code effective April 2024, and a 2025 Mayo Clinic collaboration and equity investment. However, it is a pre-scale, single-product private company that files no financial statements, so exposure is thematically direct but the opportunity is accessible only via private-market channels and cannot be underwritten on public operating fundamentals.

Ask follow-up research
Reviewed company research · researched 2026-07-22 · not an individual investment recommendation
Listing
private
Ticker
None
Exchange
None
HQ
United States
Currency
n/a
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

Leva is differentiated as a prescription, insurance-reimbursed digital therapeutic with a patented vaginal motion-sensor plus guided-app model, multi-center clinical validation (Obstetrics & Gynecology, International Urogynecology Journal), Breakthrough Device Designation (2021) for chronic fecal incontinence, and inclusion in the Digital Therapeutics Alliance product library (positioned as the first femtech entry). It competes against consumer pelvic-floor trainers (e.g., Elvie, Perifit per market context), physical therapy, drugs and surgery, and free unguided Kegels, differentiating on clinical evidence and reimbursement status. By acquiring the Leva assets from the wound-down predecessor Renovia, Inc., Axena consolidated the clearances and IP under one owner.

Scarce assets

Four FDA 510(k) clearances under product code HIR spanning urinary and chronic fecal incontinence, including a Breakthrough Device Designation; patented motion-based sensor technology; published multi-center clinical evidence in ACOG's journal; established reimbursement pathways (a dedicated HCPCS Level II code effective April 1, 2024 plus a prior pharmacy code) and payer coverage (Cigna and Blue Cross Blue Shield plans); a Mayo Clinic content collaboration and equity investment; and a distributor network (Byram Healthcare, EVERSANA, J&B Medical, OneSource Medical Group).

Products, segments, and customers

Single product line: the Leva Pelvic Health System, a prescription digital therapeutic requiring roughly five minutes of guided pelvic-floor muscle training per day, indicated for female stress/mixed/mild-to-moderate urinary incontinence and chronic fecal incontinence. Commercialization is US-focused through prescribing clinicians (urogynecology, OB/GYN, primary care), distributors and payers, with stated ambitions to extend access to sub-Saharan Africa and other low- and middle-income countries via investor Cross-Border Impact Ventures.

Theme capture

Axena captures the women's-health formalization theme directly through pelvic health: it converts an underdiagnosed, undertreated female condition (issuer/investor context cites ~32% of US adult women having at least one pelvic floor disorder) into a clinically validated, reimbursed, prescription-grade treatment pathway, formalizing care that was previously informal (unguided Kegels). Reimbursement wins (the April 2024 HCPCS code, pharmacy code, and payer coverage) and clinical-society evidence embed the product inside formal first-line care pathways.

Conditions

What must be true

  1. Insurance coverage and the HCPCS/pharmacy reimbursement pathways convert into scalable, repeatable, reimbursed prescription volume and revenue rather than remaining coverage announcements.
  2. Axena secures adequate capital and runway to reach commercial scale, given only modest disclosed Series A tranches and an interim-CEO transition in 2024.
  3. Clinicians adopt Leva as a first-line conservative option ahead of drugs and surgery, and patient adherence (about five minutes daily) sustains the published efficacy in real-world use.

Identifiable catalysts

  • Continued expansion of payer coverage alongside the dedicated HCPCS Level II code (effective April 1, 2024) driving reimbursed unit volume.
  • The Mayo Clinic collaboration (educational content live from Spring 2025) plus Mayo's equity investment as a clinical-credibility and financing signal.
  • Read-outs from ongoing clinical work (e.g., the postpartum urinary-incontinence first-line comparison trial) and any new FDA indications.
  • A potential follow-on financing round or strategic acquisition amid femtech consolidation.
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Pelvic-health treatment provider - a prescription digital therapeutic addressing female urinary and fecal incontinence within the women's-health care pathway.

Women's health formalization

Direct, pure-play exposure: Axena's entire business is the single Leva product line addressing female pelvic floor disorders, so exposure to women's-health formalization is effectively the whole company qualitatively. Absolute scale is small and undisclosed, which upgrades the seed's 'Medium' hypothesis to a qualitatively high but financially unquantified exposure.

Evidence
Issuer and regulatory disclosures explicitly name the exposure: the Leva product line, FDA 510(k) clearances for female urinary and chronic fecal incontinence (openFDA, product code HIR), the April 2024 HCPCS reimbursement code, payer coverage, and the Mayo Clinic collaboration. Limitation: as a private company Axena discloses no segment or total revenue, so the theme's dollar materiality cannot be quantified.
Materiality
disclosed — The issuer discloses a single pelvic-health product line and its female urinary/fecal-incontinence indications, and regulatory filings name the same device, so the qualitative exposure is disclosed and is the entire company. It is not marked 'estimated' in dollar terms because no revenue figures are public to size the segment.
Financial evidence

Insufficient public evidence

No compatible fiscal period has been accepted.

Limitation: Axena Health, Inc. is a privately held, venture-backed company that files with neither the SEC nor any exchange and publishes no audited financial statements; revenue, profitability, cash flow, balance-sheet data, burn, runway and valuation are not publicly available. The only public financial data are financing events, not operating results: a $25M Series A announced February 2023 (led by AXA IM Alts, with KOFA Healthcare and Avestria Ventures, per investor disclosure) and an additional $9.4M announced June 4, 2024 (adding Cross-Border Impact Ventures, per the issuer press release), plus an undisclosed Mayo Clinic equity investment (2025). Total capital raised and any post-money valuation are not disclosed; valuation is unavailable without licensed private-market data (e.g., PitchBook/Dealroom).

Risks

Material risks and break conditions

Material risks

  • Single-product concentration: the entire enterprise depends on the Leva franchise, so any clinical, reimbursement, competitive or supply setback is potentially existential.
  • Reimbursement and adoption risk: coverage announcements and the HCPCS/pharmacy codes may not convert into broad, durable payer reimbursement or clinician prescribing at scale, and DME/pharmacy channel friction can slow uptake.
  • Funding and runway risk: only modest disclosed capital (a $25M Series A plus a $9.4M extension) and a 2024 interim-CEO period, against ambitious dual US and low-/middle-income-country expansion, raise the prospect of further dilutive or down-round financing - the predecessor Renovia wound down.
  • Competitive and substitution risk: consumer pelvic-floor trainers, pharmacotherapy, surgery and free unguided Kegels all compete for the same patients.
  • Regulatory/IP dependency: clearances are of record under acquired Renovia filings on the 510(k) (product code HIR) pathway, and new indications require additional FDA clearances.

Thesis-break conditions

  • No material growth in reimbursed prescription volume over the next 12-18 months - for example, covered lives failing to expand or a major payer rescinding Leva coverage.
  • Inability to close a follow-on financing round before cash runway is exhausted, forcing a distressed transaction or wind-down as occurred with predecessor Renovia.
  • A pivotal trial (e.g., the postpartum urinary-incontinence first-line comparison) failing to demonstrate Leva's advantage over standard pelvic-floor muscle training.
Investability conclusion

Where the evidence lands

The evidence supports a genuine, direct thematic fit with women's-health formalization through a clinically validated, FDA-cleared, increasingly reimbursed pelvic-health digital therapeutic, backed by real commercial building blocks (payer coverage, an HCPCS code, a Mayo Clinic alliance and investment). It does not yet support any view on financial durability, scale or valuation, because Axena is a private, pre-scale, single-product company with no public financial statements and is accessible only via private-market channels. This is an analytical characterization of the evidence and its limits, not trading advice.

Next diligence

  1. Obtain private-market financials (revenue run-rate, gross margin, cash burn, runway) through a data room or investor access, and confirm total capital raised and the latest post-money valuation via licensed data (PitchBook/Dealroom).
  2. Quantify actual market access: breadth of payer coverage (covered lives) and reimbursed unit/claims volume under the HCPCS Level II code and the pharmacy code.
  3. Confirm current governance and leadership tenure (CEO Randy Pritchard following the 2024 interim-CEO period) and board composition.
  4. Review the full FDA clearance chain (K180637, K192270, K212495, K213913) and verify the formal transfer-of-ownership record from Renovia, Inc. to Axena Health, plus the patent estate.
  5. Track clinical trial read-outs (postpartum urinary-incontinence RCT) and any pending new FDA indications.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Axena Health - About / Company OverviewAxena Health, Inc. · primary · published n/a · accessed 2026-07-22
  2. openFDA 510(k) database - Leva Pelvic Health System clearances (applicant Renovia, Inc.; product code HIR)U.S. Food and Drug Administration (openFDA) · primary · published 2018-2022 · accessed 2026-07-22
  3. Axena Health closes on over $9 million in additional fundingAxena Health, Inc. · primary · published 2024-06-04 · accessed 2026-07-22
  4. Axena Health Enters Into Collaboration with Mayo Clinic to Expand Education and Advance First-Line Care for Female Urinary IncontinenceAxena Health, Inc. · primary · published 2025-02-06 · accessed 2026-07-22
  5. Axena Health Announces New HCPCS Code Supporting Coverage for the Leva Pelvic Health SystemAxena Health, Inc. · primary · published 2024-03-04 · accessed 2026-07-22
  6. Axena Health portfolio profile (HQ, founding, Series A funding, market context, distributors, coverage)Avestria Ventures · secondary · published n/a · accessed 2026-07-22